Pharvaris NV Return on Equity

Pharvaris NV (PHVS) currently reports a ROE of -71.52%. That is below the Healthcare sector average of 29.33%. Use the charts on this page to explore Pharvaris NV's ROE history and peer comparisons.

Pharvaris NV's ROE of -71.52% is lower than the Healthcare sector average of 29.33%. That is roughly 343.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Pharvaris NV's current -71.52% should be judged against Healthcare norms (sector average: 29.33%) and against PHVS's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -71.52%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 29.33%. From there, open related valuation or income-statement pages for Pharvaris NV, and consider following PHVS for alerts when major investors trade the stock.

Pharvaris NV is classified in the Healthcare sector. On ROE, it currently shows -71.52% versus a sector average near 29.33%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PHVS with unrelated industries.